Clinical Trial Update: Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on AQW051 assessing safety and efficacy for L-dopa induced dyskinesias in Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesias
• Parkinson Disease

Drugs mentioned

• AQW051

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Dyskinesias, Drug-induced | Phase 2 | Status: COMPLETED